- Home
- MTN vs ABVX Comparison
MTN vs ABVX Comparison
Compare MTN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- ABVX
- Stock Information
- Founded
- MTN 1997
- ABVX 2013
- Country
- MTN United States
- ABVX France
- Employees
- MTN N/A
- ABVX N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- ABVX
- Sector
- MTN Consumer Discretionary
- ABVX
- Exchange
- MTN Nasdaq
- ABVX Nasdaq
- Market Cap
- MTN 6.1B
- ABVX 5.3B
- IPO Year
- MTN 1997
- ABVX N/A
- Fundamental
- Price
- MTN $161.49
- ABVX $78.64
- Analyst Decision
- MTN Hold
- ABVX Buy
- Analyst Count
- MTN 10
- ABVX 7
- Target Price
- MTN $186.50
- ABVX $74.86
- AVG Volume (30 Days)
- MTN 475.5K
- ABVX 1.1M
- Earning Date
- MTN 09-25-2025
- ABVX 08-11-2025
- Dividend Yield
- MTN 5.51%
- ABVX N/A
- EPS Growth
- MTN 6.60
- ABVX N/A
- EPS
- MTN 7.74
- ABVX N/A
- Revenue
- MTN $2,958,444,000.00
- ABVX $11,444,012.00
- Revenue This Year
- MTN $3.74
- ABVX N/A
- Revenue Next Year
- MTN $3.78
- ABVX $41.36
- P/E Ratio
- MTN $20.82
- ABVX N/A
- Revenue Growth
- MTN 2.38
- ABVX 128.98
- 52 Week Low
- MTN $129.85
- ABVX $4.77
- 52 Week High
- MTN $199.45
- ABVX $78.49
- Technical
- Relative Strength Index (RSI)
- MTN 59.93
- ABVX 79.51
- Support Level
- MTN $152.45
- ABVX $67.15
- Resistance Level
- MTN $163.58
- ABVX $78.49
- Average True Range (ATR)
- MTN 3.05
- ABVX 2.80
- MACD
- MTN 1.39
- ABVX -1.44
- Stochastic Oscillator
- MTN 84.50
- ABVX 83.25
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.